Glasdegib for Chronic Graft-Versus-Host Disease

Exclusion Criteria

• •Hospitalization for evaluation or management of an infection within the last 8 weeks
• •Known organ dysfunction
• •* Uncontrolled cardiovascular disease, including arrhythmias, congestive heart failure
• •* Oxygen requirement
• •Addition of any new systemic immunosuppressive treatment within the last 2 weeks
• •\* Addition of new systemic immunosuppressive treatment along with glasdegib is also prohibited
• •Corrected QT (QTc) interval \> 480 ms
• •Female patients who are lactating or have a positive serum pregnancy test
• •Major surgery within 14 days before enrollment
• •\* Does not include placement of venous access device, bone marrow biopsy, GVHD diagnostic biopsy, or other routine procedures in chronic GVHD or post-transplantation care
• •Use of any concomitant medications meds that are prohibited within the past 7 days
• •Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
• •Known intolerance to glasdegib, sonidegib, or vismodegib
• •Non-hematologic malignancy within the past 2 years with the exception of:
• •* Adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer
• •* Carcinoma in situ of the cervix or breast
• •* Prostate cancer of Gleason grade 6 or less with stable prostate-specific antigen levels
• •* Cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study
• •Treatment with non-Food and Drug Administration (FDA) approved drug within 21 days of start of this trial
• •Evidence of recurrent or progressive underlying malignant disease
• •Karnofsky performance status \< 70%
• •History of non-compliance
• •Life expectancy \< 6 months
• •Grade 2 or 3 muscle cramping, or grade 1 muscle cramping that occurs at least weekly